NCT05112419已完成1 期
A Single Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Zibotentan in Healthy Participants Compared to Participants With Moderate Hepatic and Moderate Renal Impairment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUClast)
研究概览
简要总结
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.
详细描述
This is a single-dose, non-randomised, open-label, parallel-group study.
All participants will receive a single oral dose of 5 mg zibotentan under fasted conditions and will be involved in the study for approximately 5 weeks.
Approximately 12 participants will be enrolled into each one of the 2 cohorts and receive the study intervention:
- Cohort 1: 12 participants with moderate hepatic impairment and moderate renal impairment as assessed at Screening
- Cohort 2: 12 healthy participants matched for age (± 10 years), gender, and BMI (± 20%) on a group level to participants in Cohort 1
The study will comprise of the following study periods:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body weight of at least 50 kg and body mass index within the range of 18 and 35 kg/m^2 (inclusive).
- •Female of non-childbearing potential or male
- •Participants with Moderate Hepatic Impairment and Moderate Renal Impairment only (Cohort 1)
- •An estimated glomerular filtration rate (eGFR) in the range of 30 to 45 mL/min/1.73m^2 (inclusive) as determined using the Chronic Kidney Disease Epidemiology Collaboration formula, at Screening. Retesting for eGFR may be repeated twice during Screening Period.
- •Confirmed clinical diagnosis of cirrhosis with either ascites or moderate hepatic impairment (Childs-Pugh B). Supporting documents confirming the participant's hepatic impairment must be available. The participant must be classified by the Investigator or usual practitioner as Child-Pugh Class B or having radiographic or clinical evidence of ascites of any grade.
- •Stable hepatic impairment (eg, no clinically significant change in signs, symptoms, or laboratory parameters of hepatic disease status within 28 days prior to Screening, as determined by the Investigator or usual practitioner).
- •Healthy Participants only (Cohort 2)
- •Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and clinical laboratory tests.
- •An eGFR of ≥ 90 mL/min/1.73m^2 as determined using the CKD-EPI formula at Screening.
- •No clinically significant liver or kidney disease as judged by the Investigator.
排除标准
- •Medical Conditions
- •Any evidence of a clinically significant disease which in the Investigator's opinion makes it undesirable for the participant to participate in the study.
- •History of alcohol abuse or excessive intake of alcohol within 6 months prior to the Screening visit. Definition of excessive intake: an average weekly intake of >7 drinks/week for men or > 3.5 drinks/week for women. One drink is equivalent to (16 g of alcohol).
- •Positive alcohol or drug of abuse at Screening.
- •Participants with a history of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator, to drugs with a similar chemical structure or class to zibotentan.
- •Participants with known hypersensitivity/allergic reaction to paracetamol.
- •Any signs or confirmation of coronavirus disease-19 infection.
- •Participants with Moderate Hepatic Impairment and Moderate Renal Impairment only (Cohort 1)
- •Presence of unstable medical (eg, diabetes, epilepsy) or psychological conditions which, in the opinion of the Investigator, would compromise the participant's safety or successful participation in this study.
- •Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within 28 days prior to dosing (eg, infection of ascites, fever, or active gastrointestinal bleeding).
- •Severe hepatic impairment (Child-Pugh Class C Hepatic impairment), an isolated aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 5 x the upper limit of normal (ULN); or total bilirubin > 2 x ULN at time of enrolment or a concurrent increased AST and ALT of > 3 x the ULN together with a total bilirubin of > 2 x ULN. An isolated increase in bilirubin in participants with known Gilbert's syndrome is not a reason for exclusion.
- •Acute liver disease caused by drug toxicity or by an infection.
- •Presence of a hepatocellular carcinoma.
- •Liver or renal transplantation or planned within the next 3 months at Screening.
- •Receiving renal replacement therapy.
- •Recent acute or subacute renal function deterioration (eg, participants with large fluctuations of creatinine values, as judged by the Investigator, and documented within 28 days prior to Screening).
- •New York Heart Association functional heart failure Class III or intravenous or with unstable heart failure requiring hospitalisation for optimisation of heart failure treatment and who are not yet stable on heart failure therapy within 6 months prior to Screening.
- •Abnormal resting vital signs (after resting for 10 minutes) of supine systolic blood pressure> 180 mmHg or < 100 Hg; or diastolic blood pressure> 110 mmHg or < 50 mmHg.
- •Change in dose regimen of medically-required medication within the 14 days before dosing.
- •Healthy Participants only (Cohort 2)
- •History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
- •Prior/Concomitant Therapy
- •Use of strong or moderate inhibitors or inducers of CYP3A4 within 28 days prior to dose of zibotentan.
- •Use of phosphate binders (eg, aluminium hydroxide and calcium carbonate) and acid reducing agents such as cholestyramine/colestipol, ranitidine/nizatidine, or proton pump inhibitors within 3 days before and 12 hours after dosing with zibotentan.
研究组 & 干预措施
Cohort 1: Participants with moderate hepatic impairment and moderate renal impairment
Experimental
Participants will receive a single oral dose of zibotentan under fasted conditions.
干预措施: Zibotentan (Drug)
Cohort 2: Healthy participants
Experimental
Participants will receive a single oral dose of zibotentan under fasted conditions.
干预措施: Zibotentan (Drug)
结局指标
主要结局
Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUClast)
时间窗: Day 1 to Day 6
To assess the PK of a single oral dose of zibotentan in participants with moderate hepatic impairment and moderate renal impairment compared to a group of healthy matched controls
Area under plasma concentration-time curve from time zero to infinity (AUCinf)
时间窗: Day 1 to Day 6
To assess the PK of a single oral dose of zibotentan in participants with moderate hepatic impairment and moderate renal impairment compared to a group of healthy matched controls
Maximum observed plasma concentration (Cmax)
时间窗: Day 1 to Day 6
To assess the PK of a single oral dose of zibotentan in participants with moderate hepatic impairment and moderate renal impairment compared to a group of healthy matched controls
次要结局
- Apparent total non-renal body clearance of drug from plasma after extravascular administration (CLNR/F)(Day 1 to Day 6)
- Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)(Day 1 to Day 6)
- Percentage of dose excreted unchanged in urine from time of dosing (time 0) through time t [fe (0-t)](Day 1 to Day 3)
- Time to reach maximum observed plasma concentration (tmax)(Day 1 to Day 6)
- Area under plasma concentration-time curve from time zero to 72 hours post-dose (AUC [0-72])(Day 1 to Day 6)
- Terminal elimination rate constant (λz)(Day 1 to Day 6)
- Amount of unchanged drug excreted into urine from time t1 to time t2 [Ae (t1-t2)](Day 1 to Day 3)
- Renal clearance of drug from plasma, calculated as Ae0-t/AUC0-t where t is matched for urine and plasma (CLR)(Day 1 to Day 3)
- Number of participants with adverse events(Screening (Day -28 to Day -2) to Day 6)
- Area under the plasma concentration-time curve from time zero to 24 hours post-dose (AUC[0-24])(Day 1 to Day 6)
- Apparent total body clearance of drug from plasma after extravascular administration (CL/F)(Day 1 to Day 6)
- Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)(Day 1 to Day 6)
- Cumulative amount of unchanged drug excreted into urine from time of dosing (time 0) through time t [Ae (0-t)](Day 1 to Day 3)
- Percentage of dose excreted unchanged in urine from time t1 to time t2 [fe (t1-t2)](Day 1 to Day 3)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal FunctionRenal ImpairmentNCT04249908IlDong Pharmaceutical Co Ltd40
已完成
1 期
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of BalcinrenoneHepatic ImpairmentNCT06388616AstraZeneca30
已完成
1 期
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780Hepatic ImpairmentNCT06576765AstraZeneca16
已完成
1 期
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal FunctionLong QT SyndromeNCT02441829Gilead Sciences55
已完成
1 期
A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)Clostridium Difficile Associated Diarrhea (CDAD)NCT02835105Merck Sharp & Dohme LLC40